$XBI $171.86 -1% 📉
PIPELINE:
$HTBX +50% Positive interim survival data from ongoing HS-110 ph 2 NSCLC trial. source
$RMTI +30% Commercial launch in US of Triferic® AVNU for replacement of iron and maintenance of hemoglobin in patients on hemodialysis. source
$ORTX +14% Positive interim data for OTL-203 in MPS-IH. source
$ELOX +9% Publication of scientific manuscript on ELX-02 in the Journal of Cystic Fibrosis. source
$KALV +114% Phase 2 positive results across all endpoints for KVD900 as an oral on-demand treatment for HAE attacks. source
$IPHA +1% Innate Pharma advances lacutamab clinical development program. source
$AMRN +1% Update on VASCEPA regulatory process in mainland China and Hong Kong. source
$AGEN -1% New clinical response data for AGEN1181. source
FINANCIAL:
$KALV +114% Offering
$ACET -2% Offering
$CDAK -9% Offering
$ONCR +1% Offering
Comments